2 stories
Novo Nordisk entered a $2.1 billion partnership with Vivtex to develop oral delivery of biologic drugs, combining Novo's peptide expertise with Vivtex's GI formulation platform.
Novo Nordisk signed a deal worth up to $2.1 billion with Vivtex Corporation, an MIT spinoff co-founded by Bob Langer, to develop next-generation oral biologic medicines for obesity and diabetes. Vivtex's AI-driven platform screens thousands of drug delivery formulations per day with near-perfect correlation to human intestinal absorption.